What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia?

Christopher R. Flowers; Scott D. Ramsey

doi:10.1200/JCO.2018.79.3570

What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia?

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	3183-3185
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	36
Issue number	32
DOIs	https://doi.org/10.1200/JCO.2018.79.3570
State	Published - Nov 10 2018
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2018.79.3570

Cite this

@article{5704e11433994c558ac7c9b10e57250c,

title = "What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia?",

author = "Flowers, {Christopher R.} and Ramsey, {Scott D.}",

note = "Funding Information: Acerta Pharma (Inst), Infinity Pharmaceuticals (Inst), Onyx Pharmaceuticals (Inst), Janssen Pharmaceuticals (Inst), Gilead Science (Inst), Celgene (Inst), TG Therapeutics (Inst), Genentech (Inst), Roche (Inst), Pharmacyclics (Inst), AbbVie (Inst), Immune Design (Inst), BeiGene (Inst) Bayer AG (Inst), Bristol-Myers Squibb (Inst), Personalized Medicine Coalition (Inst)",

year = "2018",

month = nov,

day = "10",

doi = "10.1200/JCO.2018.79.3570",

language = "English (US)",

volume = "36",

pages = "3183--3185",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",